Dubuque Bank & Trust Co. boosted its stake in Abbott Laboratories (NYSE:ABT) by 13.5% during the second quarter, Holdings Channel reports. The institutional investor owned 88,020 shares of the healthcare product maker’s stock after buying an additional 10,442 shares during the period. Dubuque Bank & Trust Co.’s holdings in Abbott Laboratories were worth $4,279,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Sanders Morris Harris LLC increased its stake in Abbott Laboratories by 0.3% in the second quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock valued at $242,000 after buying an additional 16 shares in the last quarter. Janney Capital Management LLC increased its stake in shares of Abbott Laboratories by 0.4% in the first quarter. Janney Capital Management LLC now owns 6,229 shares of the healthcare product maker’s stock worth $276,000 after buying an additional 26 shares during the period. Alpha Windward LLC increased its stake in shares of Abbott Laboratories by 0.6% in the second quarter. Alpha Windward LLC now owns 5,434 shares of the healthcare product maker’s stock worth $264,000 after buying an additional 30 shares during the period. Johanson Financial Advisors Inc. increased its stake in shares of Abbott Laboratories by 0.5% in the second quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock worth $343,000 after buying an additional 37 shares during the period. Finally, Country Club Trust Company n.a. increased its stake in shares of Abbott Laboratories by 0.5% in the second quarter. Country Club Trust Company n.a. now owns 7,320 shares of the healthcare product maker’s stock worth $356,000 after buying an additional 38 shares during the period. 70.86% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories (NYSE ABT) traded down 0.55% during trading on Friday, hitting $49.02. 2,025,602 shares of the stock were exchanged. Abbott Laboratories has a 52 week low of $37.38 and a 52 week high of $51.13. The stock has a market capitalization of $85.17 billion, a price-to-earnings ratio of 68.66 and a beta of 1.07. The firm has a 50-day moving average of $49.15 and a 200-day moving average of $45.90.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.60 by $0.02. The company had revenue of $6.64 billion during the quarter, compared to analysts’ expectations of $6.63 billion. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. Abbott Laboratories’s quarterly revenue was up 24.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.55 earnings per share. Equities research analysts anticipate that Abbott Laboratories will post $2.49 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 15th. Stockholders of record on Friday, July 14th were given a $0.265 dividend. The ex-dividend date of this dividend was Wednesday, July 12th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.15%. Abbott Laboratories’s payout ratio is presently 149.30%.

TRADEMARK VIOLATION NOTICE: “Abbott Laboratories (ABT) Stake Raised by Dubuque Bank & Trust Co.” was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/18/abbott-laboratories-abt-stake-raised-by-dubuque-bank-trust-co.html.

A number of analysts have weighed in on ABT shares. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b” rating in a report on Monday, July 3rd. Royal Bank Of Canada reissued a “buy” rating on shares of Abbott Laboratories in a report on Monday, May 15th. Jefferies Group LLC reissued a “buy” rating and issued a $51.00 price target (up from $50.00) on shares of Abbott Laboratories in a report on Friday, May 12th. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $49.00 price target for the company in a report on Tuesday, May 16th. Finally, Stifel Nicolaus increased their price target on shares of Abbott Laboratories from $49.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, May 31st. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $52.14.

In other news, insider Sharon J. Bracken sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total value of $98,320.00. Following the completion of the sale, the insider now owns 28,806 shares of the company’s stock, valued at $1,416,102.96. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Stephen R. Fussell sold 196,550 shares of the business’s stock in a transaction dated Thursday, June 8th. The shares were sold at an average price of $46.00, for a total transaction of $9,041,300.00. Following the completion of the sale, the insider now directly owns 221,488 shares of the company’s stock, valued at approximately $10,188,448. The disclosure for this sale can be found here. In the last three months, insiders sold 218,702 shares of company stock valued at $10,149,733. 0.76% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.